KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Cash from Financing Activities: 2009-2024

Historic Cash from Financing Activities for Arbutus Biopharma (ABUS) over the last 16 years, with Dec 2024 value amounting to $52.0 million.

  • Arbutus Biopharma's Cash from Financing Activities fell 52.45% to $844,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year decrease of 89.88%. This contributed to the annual value of $52.0 million for FY2024, which is 69.66% up from last year.
  • Per Arbutus Biopharma's latest filing, its Cash from Financing Activities stood at $52.0 million for FY2024, which was up 69.66% from $30.6 million recorded in FY2023.
  • Over the past 5 years, Arbutus Biopharma's Cash from Financing Activities peaked at $137.2 million during FY2021, and registered a low of $30.6 million during FY2023.
  • Over the past 3 years, Arbutus Biopharma's median Cash from Financing Activities value was $31.8 million (recorded in 2022), while the average stood at $38.2 million.
  • Per our database at Business Quant, Arbutus Biopharma's Cash from Financing Activities skyrocketed by 131.59% in 2020 and then slumped by 76.82% in 2022.
  • Yearly analysis of 5 years shows Arbutus Biopharma's Cash from Financing Activities stood at $86.7 million in 2020, then spiked by 58.20% to $137.2 million in 2021, then plummeted by 76.82% to $31.8 million in 2022, then declined by 3.67% to $30.6 million in 2023, then surged by 69.66% to $52.0 million in 2024.